the medical history (disease and treatment), the site and degree of stenosis, and medical procedures undertaken after coronary angiography. The information on CAD risk factors and clinical laboratory values was collected at registration and every 6 months thereafter for 3 years. The primary endpoint was "all events", defined as cardiovascular events and all-cause mortality. Detailed information was collected regarding cardiovascular events, all-cause mortality, treatment, and outcome. All events registered in the database were defined by all-cause mortality and cardioand cerebrovascular events. Angiographic restenosis found during routine coronary angiography without symptoms was excluded.
We divided the 8,832 patients into quartiles based on baseline UA level and compared the incidence of all events and cardiac events among the 4 groups. Study patients were placed in a quartiles regardless of hyperuricemic medication. The group was also divided into 2 subgroups according to the changes in UA at 6 months after registration. The increased UA group included patients with a UA increasing by more than 1.0 mg/dl and the non-increased UA group included those whose UA did not change or increased by <1.0 mg/dl.
To reduce the effect of medications that directly affect serum UA level, we also conducted propensity score matching. A propensity score for each patient was calculated by multivariate logistic regression analysis, taking into account the CAD risk factors and medications that directly affect the serum UA level, including α1-blockers, calcium-channel blockers, angiotensin-converting enzyme inhibitors, diuretics, losartan, uricosuric drugs, and UA synthesis inhibitors. We then divided 4,206 patients into the highest quartile (UA ≥6.8 mg/dl) and the rest, and compared the results.
Statistical Analysis
For patient baseline characteristics, the difference in percentage was evaluated among the 4 groups by χ2 test. Continuous variables are expressed as mean ± standard deviation, and the difference among the 4 groups was evaluated by Kruscal-Wallis test. Cumulative incidence of events was estimated by the Kaplan-Meier product-limit method and compared by log-rank test in the events. The multivariate analysis was performed using the Cox hazard ratio (HR) model, and expressed with 95% confidence intervals (CI). Statistical analysis was performed with SAS version 8.02 (SAS Institute Inc, Cary, NC, USA).
Results

Baseline Patient Characteristics
Baseline patient characteristics were compared among the 4 groups ( Table 1) : there were significant differences among the quartiles in age, sex, the number of stenoses, hypertension, hyperlipidemia, impaired glucose tolerance, obesity, smokers, alcohol users, and congestive heart failure (CHF). However, there was no difference in the rate of CAD familial history and left main CAD (LMT). Table 2 shows the association between baseline UA and subsequent events by sex and each endpoint. The total incidence rates of all events were significantly different among the 4 groups (58.3, 56.5, 61.2, 76.3/1,000 patients-year, P< 0.001). Cardiac mortality and morbidity for total and female patients were significantly different among quartiles, but not for male patients. When the cardiac events were divided into CAD events (ie, acute myocardial infarction, unstable angina pectoris, and coronary artery bypass graft) and other events (ie, arrhythmia, CHF, and cardiopulmonary arrest on arrival), the incidence of CAD events was not significantly different among quartiles. However, other events were significantly different. On the other hand, the incidence rate of cerebral death and events did not differ among the 4 groups.
Incidence Rates of Events
Cumulative Incidence of Events
The cumulative incidence of all events and cardiac events that occurred during the 3 years in the quartiles was compared with a Kaplan-Meier curve (Figure 1 ). The HRs were significantly different among quartiles (1.00, 0.99, 1.06, 1.31, P<0.001). The results by sex showed a similar trend (Figures 2a,b) .
The cumulative incidence of all events in the patients with UA increasing by ≥1.0 mg/dl after 6 months compared with those with unchanged UA is shown by Kaplan-Meier curve (Figure 3a) . The event rate in the increased UA group was 70.6, vs 58.8/1,000 patient-years in the group with no increase (P=0.042).
Association of UA With Risk for All Events
The HR for all events, including cardiac and cerebrovascular events, and all-cause mortality was 1.25 (1.07-1.45, P<0.01) in the highest quartile when adjusted for sex, age, hyperlipidemia, impaired glucose tolerance, hypertension, obesity, smoking, drinking, CAD familial history, CHF, LMT, and the number of stenoses, suggesting that elevated serum UA was an independent predictor for cardiovascular events ( Table 3) .
Propensity Score Analysis
Baseline patient characteristics adjusted by propensity score analysis were compared between the 2 groups ( Table 4) . Even after adjustment for CAD risk factors and medications directly affecting serum UA level, the incidence rate of all events was significantly higher in the highest quartile than in the others (Table 5) . When analyzed by each endpoint, results were similar to that of all events, except for mortality. The HR calculated by the Cox HR model was 1.23 (95%CI 1.06 -1.43, P<0.01), which was similar to that of all patients (Table 6 ). However, the cumulative incidence of all events in the patients with UA increased ≥1.0 mg/dl after 6 months was not significantly different from that of patients with unchanged UA (Figure 3b ).
Discussion
The Japanese Coronary Artery Disease Study 11 targeted patients who had a severe stenosis in their coronary arteries diagnosed by coronary angiography, which conferred an equivalent risk of CAD as in Western patients. We performed a subanalysis of cardio-and cerebrovascular events and all-cause mortality among quartiles based on baseline UA. The UA of the highest quartile was >6.8 mg/dl. The incidence of cardio-and cerebrovascular events and all-cause mortality was higher in the highest quartile than in the others. The results demonstrate that elevated UA was an important risk factor for cardio-and cerebrovascular events and allcause mortality combined in patients who had severe coronary artery stenosis. Cox's proportional hazard regression analysis showed that the HR for all events was 1.25 (95%CI 1.07-1.45, P<0.01) in the highest quartile (UA ≥6.8 mg/dl). It showed that UA was still an independent predictor for all events, including all-cause death and cardio-cerebrovascular events.
A similar relationship between elevated UA and cardiovascular events, such as myocardial infarction and stroke, has been demonstrated in numerous large-scale clinical studies. In the NHANES I Study, 13 a high level of UA was an independent predictor for cardiovascular disease in both men and women. The incidence of cardiac death increased in men with UA >7.0 mg/dl, and in women with UA >5.6 mg/dl. Bickel et al reported similar findings to the Japanese Coronary Artery Disease Study in patients with CAD diagnosed by coronary angiography. The HR for death in their report was 1.30 in women and 1.39 in men, 14 suggesting that elevated UA is an independent risk factor for death. According to our study results, the HR for cardiac events of 1.25 (95%CI 1.07-1.45, P<0.01) in Japanese patients was comparable to the HR for death of patients in Western countries. In Japan, Tomita et al's employee survey 9 found that in patients with UA >8.5 mg/dl, the HR for death from CAD and for cerebrovascular death increased to 1.7 and 2.6, respectively. In our study, the highest quartile showed the same tendency when we focused only on the endpoint of cardiac events. However, the HR did not increase for cerebral events. Although the incidence of cerebral events is greater than that of cardiac events in the Japanese general population, patients with severe coronary stenosis were targeted in the Japanese Coronary Artery Disease Study, which may be reflected in our results that the incidence of cardiac events was much greater than that of cerebral events.
When the cardiac events were divided into CAD events and other events, for other events only there was a significant difference among baseline UA quartiles in terms of both mortality and morbidity. Strasak et al reported similar results in their cohort study of 83,683 male patients. 15 In the present study, CHF accounted for approximately 75% of other events. Recent in vitro and in vivo findings suggest that UA contributes directly to endothelial dysfunction by inducing antiproliferative effects and impairing nitric oxide production, 16 thus causing a deterioration of CHF. Sakai et al 17 recently demonstrated that in patients with mild to Abbreviations see in Table 1 . Abbreviations see in Tables 1,2 . Tables 1,3. severe CHF, not only high plasma concentrations of B-type natriuretic peptide but also high UA concentrations were likely to be independent predictors of mortality. They concluded that monitoring both of these parameters may be important in the management of CHF patients. In the present study, the UA level was not significantly associated with the incidence of CAD, which is consistent with the findings of previous studies including the Framingham Heart Study, 2 Wannamethee et al, 18 and the ARIC study. 19 On the other hand, it has been reported that human atherosclerotic plaque contains a considerable amount of UA, and hyperuricemia may promote thrombus formation via purine metabolism. 20, 21 Strasak et al 22 reported that UA is an independent predictor for acute and subacute forms of CAD, so we cannot conclude that there is no association between UA and CAD. However, UA may have a stronger effect on dysfunction of the heart than CAD.
When analyzed by sex, the association of UA with event risk was higher in female patients than in male patients. In the NHANES I Study 13 and ARIC study 19 the cut-off value increasing CAD risk was higher by approximately 1 mg/dl in male patients compared with female patients. In the present study, we assumed that the incidence rate of female patients was high because we used the UA cut-off value of 6.8 mg/dl to divide patients into quartiles, regardless of sex.
According to the Japanese guidelines, hyperuricemia is defined as UA ≥7.0 mg/dl and the target UA level is <6.0 mg/dl, which may be reasonable, because in the present study the incidence rate of events increased in male patients with UA ≥6.8 mg/dl.
In this analysis, the group in which UA increased more than 1.0 mg/dl after 6 months had more events than the other group, regardless of the UA level. Hakota et al 10 reported that a 1.0 mg/dl increase in UA increased the HR of myocardial infarction to 1.17 in men and 1.23 in women. However, in our propensity score analysis, taking into account CAD risk factors and medications directly affecting serum UA level, no difference was observed between patients with UA change ≥1.0 mg/dl and UA change <1.0 mg/dl after 6 months. We assumed that the presence of complications and medications affecting serum UA level caused cardiovascular events. Because we can only control complications, but not completely cure them, management of serum UA level by medication is important for reducing cardiovascular events.
Study Limitations
This study was observational and although confounding factors were adjusted by multivariate Cox regression analysis, and the results were still consistent after propensity score matching, an interventional study must be conducted to examine the effect of UA lowering treatment on cardiovascular disease.
In conclusion, hyperuricemia is an independent predictor of cardiovascular events and all-cause mortality combined in patients with severe coronary artery stenosis.
